Detalhe da pesquisa
1.
Prognostic impact of 'multi-hit' versus 'single hit' TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases.
Haematologica
; 2024 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38813716
2.
Clinical implications of additional chromosomal abnormalities in adult acute myeloid leukemia with inv (16)/t(16;16)/CBFB::MYH11.
Eur J Haematol
; 112(6): 964-974, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38388794
3.
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers.
Am J Hematol
; 99(4): 606-614, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38342997
4.
Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia.
Cancer
; 129(6): 934-945, 2023 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36545710
5.
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors.
Am J Hematol
; 97(3): 322-328, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34981560
6.
Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia.
Am J Hematol
; 95(11): 1288-1295, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32681739
7.
Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.
Blood
; 129(10): 1275-1283, 2017 03 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28003274
8.
Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma.
Am J Hematol
; 93(1): 91-99, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29047158
9.
Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.
Cancer
; 123(24): 4851-4859, 2017 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28841236
10.
Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes.
Cancer
; 123(6): 994-1002, 2017 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28094841
11.
Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma.
Clin Gastroenterol Hepatol
; 15(11): 1791-1799, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28579181
12.
Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival.
Am J Hematol
; 97(7): E232-E235, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35338673
13.
Reassessing hepatocellular carcinoma staging in a changing patient population.
Oncology
; 86(2): 63-71, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24401634
14.
Advancements and Challenges in the Treatment of AML.
Am Soc Clin Oncol Educ Book
; 44(3): e438662, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38662975
15.
CSF3R mutated myeloid neoplasms: beyond chronic neutrophilic leukemia.
Hum Pathol
; 2024 Jun 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38879086
16.
Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era.
Blood Adv
; 2024 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38739724
17.
Multidisciplinary management of hepatocellular carcinoma.
Recent Results Cancer Res
; 190: 247-59, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-22941025
18.
Prognostic significance of hyperdiploidy in adult acute myeloid leukemia.
Am J Hematol
; 93(11): E357-E360, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30074261
19.
Novel Therapies in Myelodysplastic Syndrome: Where Do Venetoclax and Isocitrate Dehydrogenase Inhibitors Fit in?
Cancer J
; 29(3): 188-194, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37195775
20.
Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
Leukemia
; 37(4): 799-806, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36807649